Close Menu

tuberculosis

The test simultaneously identifies Mycobacterium tuberculosis and resistance to first-line drug therapy rifampicin.

Agilent's Human CNV Association 2x105K microarray, based on a design by the Wellcome Trust Case Control Consortium, is the company's second catalog CNV chip and was designed for studying associations between genomic CNVs and disease.

BioArray Briefs: 2009.04.07

Premium

CGC Genetics, Nuvera Biosciences, Veridex, ImaGenes, CapitalBio, Fisher Healthcare, Osmetech, National Institutes of Health, Clinical Data, Cogenics, UK Biotechnology and Biological Sciences Research Council

Several of the company's microarray-based tests have been certified in China and Europe.

Papers of Note: Mar 10, 2009

Premium

Sequencing-Related Papers of Note, Feb. 2009

Snippets: Mar 4, 2009

Premium

DNAPrint, Laboratory Corporation of America, Duke University, Lab21, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Diseases and Stroke, and more …

Lab21 gains access to a phage amplification technology that it is being used to develop rapid tests for active and drug-resistant tuberculosis.

Bioinformatics

Kauffman Foundation, MIT, BioAMPS, University of Colorado, Endo Pharma, Harvard, Galapagos, Flanders Institute of Biotechnology, and more …

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.